Opthea Valuation
Is OPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPT (A$0.63) is trading below our estimate of fair value (A$19.39)
Significantly Below Fair Value: OPT is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPT?
Key metric: As OPT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is OPT's PB Ratio? | |
|---|---|
| PB Ratio | -6.6x |
| Book | -US$75.81m |
| Market Cap | US$528.30m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2122.3x |
| Enterprise Value/EBITDA | -2.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does OPT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.3x | ||
CUV Clinuvel Pharmaceuticals | 3.2x | 26.2% | AU$669.3m |
ARX Aroa Biosurgery | 2.6x | 56.3% | AU$219.0m |
IMM Immutep | 2.2x | 38.6% | AU$443.6m |
RAC Race Oncology | 13.3x | 0.1% | AU$231.8m |
OPT Opthea | n/a | 61.9% | AU$812.5m |
Price-To-Book vs Peers: OPT has negative equity and a Price-To-Book Ratio (-6.6x) compared to the peer average (5.3x).
Price to Book Ratio vs Industry
How does OPT's PB Ratio compare vs other companies in the AU Biotechs Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
BNO Bionomics | 0.3x | -36.0% | US$9.52m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: OPT has negative equity and a Price-To-Book Ratio (-6.6x) compared to the Australian Biotechs industry average (3.1x).
Price to Book Ratio vs Fair Ratio
What is OPT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -6.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate OPT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$0.63 | AU$0.91 +46.3% | 61.9% | AU$1.63 | AU$0.28 | n/a | 4 |
| Nov ’25 | AU$0.80 | AU$0.91 +14.3% | 61.9% | AU$1.63 | AU$0.28 | n/a | 4 |
| Oct ’25 | AU$0.83 | AU$0.91 +10.2% | 61.9% | AU$1.63 | AU$0.28 | n/a | 4 |
| Sep ’25 | AU$0.58 | AU$0.79 +35.0% | 64.4% | AU$1.63 | AU$0.28 | n/a | 4 |
| Aug ’25 | AU$0.45 | AU$0.79 +77.4% | 64.4% | AU$1.63 | AU$0.28 | n/a | 4 |
| Jul ’25 | AU$0.34 | AU$0.87 +152.0% | 64.9% | AU$1.63 | AU$0.28 | n/a | 3 |
| Jun ’25 | AU$0.51 | AU$0.88 +72.0% | 63.4% | AU$1.63 | AU$0.30 | n/a | 3 |
| May ’25 | AU$0.62 | AU$0.90 +44.7% | 65.0% | AU$1.69 | AU$0.30 | n/a | 3 |
| Apr ’25 | AU$0.74 | AU$0.79 +6.4% | 82.9% | AU$1.71 | AU$0.30 | n/a | 3 |
| Mar ’25 | AU$0.67 | AU$0.84 +26.0% | 86.8% | AU$1.88 | AU$0.30 | n/a | 3 |
| Feb ’25 | AU$0.48 | AU$0.84 +75.8% | 86.8% | AU$1.88 | AU$0.30 | n/a | 3 |
| Jan ’25 | AU$0.57 | AU$1.15 +101.0% | 71.7% | AU$2.05 | AU$0.30 | n/a | 4 |
| Dec ’24 | AU$0.49 | AU$1.15 +133.8% | 71.7% | AU$2.05 | AU$0.30 | n/a | 4 |
| Nov ’24 | AU$0.33 | AU$1.15 +247.1% | 71.7% | AU$2.05 | AU$0.30 | AU$0.80 | 4 |
| Oct ’24 | AU$0.33 | AU$1.29 +291.8% | 77.6% | AU$2.64 | AU$0.30 | AU$0.83 | 4 |
| Sep ’24 | AU$0.44 | AU$1.10 +149.4% | 99.4% | AU$2.64 | AU$0.30 | AU$0.58 | 3 |
| Aug ’24 | AU$0.59 | AU$1.65 +177.4% | 53.6% | AU$2.80 | AU$0.65 | AU$0.45 | 3 |
| Jul ’24 | AU$0.55 | AU$1.65 +200.1% | 53.6% | AU$2.80 | AU$0.65 | AU$0.34 | 3 |
| Jun ’24 | AU$0.60 | AU$1.65 +175.0% | 53.6% | AU$2.80 | AU$0.65 | AU$0.51 | 3 |
| May ’24 | AU$0.71 | AU$1.65 +130.8% | 53.6% | AU$2.80 | AU$0.65 | AU$0.62 | 3 |
| Apr ’24 | AU$0.73 | AU$1.65 +126.1% | 53.6% | AU$2.80 | AU$0.65 | AU$0.74 | 3 |
| Mar ’24 | AU$0.84 | AU$1.65 +96.5% | 53.6% | AU$2.80 | AU$0.65 | AU$0.67 | 3 |
| Feb ’24 | AU$0.95 | AU$1.70 +79.0% | 48.7% | AU$2.80 | AU$0.80 | AU$0.48 | 3 |
| Jan ’24 | AU$0.92 | AU$1.70 +85.8% | 48.7% | AU$2.80 | AU$0.80 | AU$0.57 | 3 |
| Dec ’23 | AU$0.94 | AU$1.70 +79.9% | 48.7% | AU$2.80 | AU$0.80 | AU$0.49 | 3 |
| Nov ’23 | AU$1.00 | AU$1.70 +70.0% | 48.7% | AU$2.80 | AU$0.80 | AU$0.33 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Medical Developments International
AU$47.9m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.42
7D
-2.3%
1Y
-44.8%
AVITA Medical
US$339.9m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.90
7D
2.1%
1Y
25.0%
Little Green Pharma
AU$39.2m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
6.1%